(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 1.84% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Bio Rad Laboratories's revenue in 2026 is $2,589,300,000.On average, 7 Wall Street analysts forecast BIO's revenue for 2026 to be $69,332,087,775, with the lowest BIO revenue forecast at $66,337,412,175, and the highest BIO revenue forecast at $72,647,621,475. On average, 7 Wall Street analysts forecast BIO's revenue for 2027 to be $71,150,283,675, with the lowest BIO revenue forecast at $66,337,412,175, and the highest BIO revenue forecast at $75,802,726,125.
In 2028, BIO is forecast to generate $73,182,384,975 in revenue, with the lowest revenue forecast at $67,219,771,950 and the highest revenue forecast at $78,957,830,775.